ES2095337T3 - Preparacion de pranoprofen de liberacion sostenida. - Google Patents

Preparacion de pranoprofen de liberacion sostenida.

Info

Publication number
ES2095337T3
ES2095337T3 ES92101830T ES92101830T ES2095337T3 ES 2095337 T3 ES2095337 T3 ES 2095337T3 ES 92101830 T ES92101830 T ES 92101830T ES 92101830 T ES92101830 T ES 92101830T ES 2095337 T3 ES2095337 T3 ES 2095337T3
Authority
ES
Spain
Prior art keywords
sustained release
components
preparation
pranoprophen
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92101830T
Other languages
English (en)
Inventor
Masunari Fushimi
Hideyoshi Kanbe
Shuichi Kasai
Akira Iwasa
Yoichi Sawayanagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dojin Iyaku Kako Co Ltd
SSP Co Ltd
Original Assignee
Dojin Iyaku Kako Co Ltd
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dojin Iyaku Kako Co Ltd, SSP Co Ltd filed Critical Dojin Iyaku Kako Co Ltd
Application granted granted Critical
Publication of ES2095337T3 publication Critical patent/ES2095337T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTA UNA PREPARACION DE PRANOPROFENO DE LIBERACION SOSTENIDA. LA PREPARACION COMPRENDE UNA CANTIDAD EFECTIVA DE PRANOPROFENO Y UN O MAS COMPONENTES DE LIBERACION SOSTENIDA ELEGIDOS ENTRE EL GRUPO QUE CONSISTE EN COMPONENTES ACEITOSOS, COMPONENTES SOLUBLES EN AGUA, COMPONENTES INDISOLUBLES EN AGUA, Y COMPONENTES SOLUBLES INTESTINALMENTE. CONTROLA LA LIBERACION DE PRANOPROFENO Y REDUCE LA CONCENTRACION MAXIMA DE PRANOPROFENO EN LA SANGRE, MANTENIENDO SU CONCENTRACION EN LA SANGRE A UN CIERTO NIVEL DURANTE UN LARGO PERIODO DE TIEMPO. REDUCE LOS RIESGOS DE EFECTOS SECUNDARIOS Y PUEDE TRATAR EFICAZMENTE ENFERMEDADES CON UNA O DOS DOSIS AL DIA.
ES92101830T 1991-02-08 1992-02-04 Preparacion de pranoprofen de liberacion sostenida. Expired - Lifetime ES2095337T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3017769A JP2829794B2 (ja) 1991-02-08 1991-02-08 徐放性経口投与型プラノプロフェン製剤

Publications (1)

Publication Number Publication Date
ES2095337T3 true ES2095337T3 (es) 1997-02-16

Family

ID=11952925

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92101830T Expired - Lifetime ES2095337T3 (es) 1991-02-08 1992-02-04 Preparacion de pranoprofen de liberacion sostenida.

Country Status (8)

Country Link
US (1) US5225206A (es)
EP (1) EP0498372B1 (es)
JP (1) JP2829794B2 (es)
KR (1) KR920016097A (es)
CA (1) CA2060493A1 (es)
DE (1) DE69214310T2 (es)
ES (1) ES2095337T3 (es)
TW (1) TW271396B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2860729B2 (ja) * 1992-03-10 1999-02-24 エスエス製薬株式会社 プラノプロフェン懸濁シロップ剤
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US20010003811A1 (en) * 1998-09-23 2001-06-14 Warren Rufus W. Method and system for rendering a view such as an arrangement for creating a lighting pattern
ATE307808T1 (de) * 1999-03-24 2005-11-15 Scherer Technologies Inc R P Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
US6866906B2 (en) 2000-01-26 2005-03-15 International Paper Company Cut resistant paper and paper articles and method for making same
AU2001233066B2 (en) 2000-01-26 2005-04-21 International Paper Company Low density paperboard articles
EP2236161A1 (en) 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
WO2005044262A1 (en) * 2003-10-29 2005-05-19 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
HRP20140361T1 (hr) * 2003-12-16 2014-05-23 Nektar Therapeutics Monodisperzne smjese pegiliranog naloksola
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
JPWO2024058093A1 (es) * 2022-09-16 2024-03-21

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS597115A (ja) * 1982-07-02 1984-01-14 Yoshitomi Pharmaceut Ind Ltd 消炎鎮痛外用剤
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
DE3678644D1 (de) * 1985-08-16 1991-05-16 Procter & Gamble Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
JPS6468317A (en) * 1987-09-08 1989-03-14 Dainippon Pharmaceutical Co Durative preparation
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
JPH0341020A (ja) * 1989-07-10 1991-02-21 Showa Denko Kk 医薬品組成物
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent

Also Published As

Publication number Publication date
EP0498372B1 (en) 1996-10-09
CA2060493A1 (en) 1992-08-09
DE69214310D1 (de) 1996-11-14
JP2829794B2 (ja) 1998-12-02
TW271396B (es) 1996-03-01
DE69214310T2 (de) 1997-03-06
KR920016097A (ko) 1992-09-24
JPH04257519A (ja) 1992-09-11
EP0498372A1 (en) 1992-08-12
US5225206A (en) 1993-07-06

Similar Documents

Publication Publication Date Title
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
ES2167611T3 (es) Formulaciones de gel que contienen factores de crecimiento.
ES2194050T3 (es) Uso de bisfosfonatos para inhibir la resorcion osea tras la implantacion de una protesis osea.
ES2140658T3 (es) Sistemas terapeuticos transdermicos que contienen esteroides sexuales.
AR001739A1 (es) Uso de un vasodilatador para la producción de una formulación para modular la repuesta sexual humanay dicha formulación
YU47899B (sh) Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
FR2617042B1 (fr) Dispositif de chirurgie de la cornee
NO905437D0 (no) Kateteranordning for hindring av blodlekkasje.
FR2522969B1 (fr) Connecteur pour tubulure medicale et poche pour solution medicale utilisant ce connecteur
KR920019342A (ko) 골질환 치료제
DE3850492D1 (de) Chirurgisches bewässerungs- und absaugesystem.
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
FI923357A0 (fi) Framstaellning av fettsyramediciner.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
IT8722682A0 (it) Compressa per uso oftalmico e rilascio controllato della sostanza attiva.
DK0476113T3 (da) Lægemiddel til behandling af hyperlipidæmi og/eller atherosklerose
ES2094834T3 (es) Dispositivo para el lavado, para finalidades terapeuticas o de higiene, de conductos internos humanos o animales.
ES2158094T3 (es) Sales de adicion de acido de compuestos de 2,3,4,5-tetrahidro-1h-3-benzazepina.
GB9227123D0 (en) Method
DK178188D0 (da) Antivirusmiddel
ATE43498T1 (de) Pyrethroid enthaltende pharmazeutische zubereitungen.
ES2059633T3 (es) 2-terc.-butil-4-cloro-5-(4-terc.-butilbenciltio)-3(2h)-piridazinona para la lucha contra los moluscos.
TR199701617T1 (xx) �iftliklerde �retilen bal�klarda g�r�len parazitlerle m�cadelede kullan�lacak bir ajan.
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 498372

Country of ref document: ES